Related by context. Frequent words. (Click for all words.) 62 Randomized controlled 59 substudy 59 placebo controlled clinical 59 Ischemic 59 multicenter randomized 58 Thrombolysis 58 thromboembolic 58 prospectively defined 58 Diabetic Macular Edema 58 subanalysis 58 secondary efficacy endpoints 58 double blinded placebo 58 colorectal adenomas 57 Cardiovascular Events 57 DCCT 57 Multicenter 57 multicenter randomized double 57 GSK# [001] 57 nonrandomized 56 Phase Ib clinical 56 SABCS 56 prospective observational 56 ACRIN 56 elotuzumab 56 Antihypertensive 56 placebo controlled clinical trials 56 neoadjuvant 56 blinded placebo controlled 56 Pioglitazone 56 placebo controlled trials 56 tolvaptan 56 multicentre 55 placebo controlled studies 55 phase IIa 55 lymphadenectomy 55 Phase III Clinical Trial 55 Meta Analysis 55 nab paclitaxel 55 Phase 1b trial 55 subgroup analyzes 55 prospective multicenter 55 dose titration 55 Pivotal Trial 55 concomitant medications 55 Pharmacokinetic 55 sipuleucel T 55 irbesartan 55 Phase III randomized 55 TRITON TIMI 55 placebo controlled randomized 55 composite endpoint 55 #mg/day [001] 55 prospective cohort 55 Monotherapy 55 Randomized Controlled Trial 55 NSABP 55 NHANES III 55 Cardiovascular Risk 54 placebo controlled Phase 54 RCTs 54 coadministration 54 6R BH4 54 RRMS patients 54 randomized controlled clinical trials 54 Pivotal Phase 54 acute coronary syndromes ACS 54 TOLAMBA 54 randomized clinical 54 Pivotal Phase III 54 lipid lowering therapy 54 Postmenopausal Women 54 glatiramer acetate 54 Rosuvastatin 54 QTc 54 pharmacokinetic PK 54 coronary revascularization 54 AREDS 54 phase IIb clinical 54 Eye Disease 54 primary hypercholesterolemia 54 ximelagatran 54 multicenter clinical 54 metastatic castration resistant 54 cardiovascular morbidity 53 prespecified 53 ISTODAX 53 Dyslipidemia 53 pramlintide 53 achieved statistical significance 53 ALLHAT 53 randomized 53 Secondary endpoints 53 confirmatory Phase III 53 normotensive 53 observational studies 53 olmesartan 53 Chronic Heart Failure 53 cerebrovascular events 53 placebo controlled 53 pharmacodynamic effects 53 dose regimens